These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 17396533

  • 1. Psychometric testing of the Americanized version of the Guy's Neurological Disability Scale.
    Fraser C, McGurl J.
    J Neurosci Nurs; 2007 Feb; 39(1):13-9. PubMed ID: 17396533
    [Abstract] [Full Text] [Related]

  • 2. Psychometric properties of the Italian version of the Guy's Neurological Disability Scale.
    Pappalardo A, Patti F.
    Funct Neurol; 2010 Feb; 25(4):223-33. PubMed ID: 21388584
    [Abstract] [Full Text] [Related]

  • 3. The Guy's Neurological Disability Scale in patients with multiple sclerosis: a clinical evaluation of its reliability and validity.
    Rossier P, Wade DT.
    Clin Rehabil; 2002 Feb; 16(1):75-95. PubMed ID: 11837529
    [Abstract] [Full Text] [Related]

  • 4. Validation of the Brazilian version of Guy's neurological disability scale.
    Araujo CR, Simão LM, Ybarra MI, Faria NV, Botelho CM, Moreira MA, Teixeira AL, Lana-Peixoto MA.
    Arq Neuropsiquiatr; 2007 Sep; 65(3A):615-8. PubMed ID: 17876401
    [Abstract] [Full Text] [Related]

  • 5. Validation of the Guy's Neurological Disability Scale as a screening tool for cognitive impairment in multiple sclerosis.
    Akatani R, Chihara N, Tachibana H, Koto S, Kowa H, Kanda F, Matsumoto R, Toda T.
    Mult Scler Relat Disord; 2019 Oct; 35():272-275. PubMed ID: 31442905
    [Abstract] [Full Text] [Related]

  • 6. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.
    Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH.
    Mult Scler; 2004 Feb; 10(1):55-60. PubMed ID: 14760953
    [Abstract] [Full Text] [Related]

  • 7. The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis.
    Sharrack B, Hughes RA.
    Mult Scler; 1999 Aug; 5(4):223-33. PubMed ID: 10467380
    [Abstract] [Full Text] [Related]

  • 8. Comparisons of patient self-report, neurologic examination, and functional impairment in MS.
    Hoogervorst EL, van Winsen LM, Eikelenboom MJ, Kalkers NF, Uitdehaag BM, Polman CH.
    Neurology; 2001 Apr 10; 56(7):934-7. PubMed ID: 11294932
    [Abstract] [Full Text] [Related]

  • 9. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL, Zwemmer JN, Jelles B, Polman CH, Uitdehaag BM.
    Mult Scler; 2004 Oct 10; 10(5):569-74. PubMed ID: 15471375
    [Abstract] [Full Text] [Related]

  • 10. One year changes in disability in multiple sclerosis: neurological examination compared with patient self report.
    Hoogervorst EL, Eikelenboom MJ, Uitdehaag BM, Polman CH.
    J Neurol Neurosurg Psychiatry; 2003 Apr 10; 74(4):439-42. PubMed ID: 12640058
    [Abstract] [Full Text] [Related]

  • 11. Factor structure of Guy's Neurological Disability Scale in a sample of Dutch patients with multiple sclerosis.
    Mokkink LB, Knol DL, Uitdehaag BM.
    Mult Scler; 2011 Dec 10; 17(12):1498-503. PubMed ID: 21828196
    [Abstract] [Full Text] [Related]

  • 12. Assessing fatigue in multiple sclerosis: Dutch modified fatigue impact scale.
    Kos D, Kerckhofs E, Nagels G, D'Hooghe BD, Duquet W, Duportail M, Ketelaer P.
    Acta Neurol Belg; 2003 Dec 10; 103(4):185-91. PubMed ID: 15008502
    [Abstract] [Full Text] [Related]

  • 13. The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment.
    Hoogervorst EL, de Jonge P, Jelles B, Huyse FJ, Heeres I, van der Ploeg HM, Uitdehaag BM, Polman CH.
    J Neurol Neurosurg Psychiatry; 2003 Jan 10; 74(1):20-4. PubMed ID: 12486260
    [Abstract] [Full Text] [Related]

  • 14. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.
    Wade DT, Young CA, Chaudhuri KR, Davidson DL.
    J Neurol Neurosurg Psychiatry; 2002 Sep 10; 73(3):246-9. PubMed ID: 12185153
    [Abstract] [Full Text] [Related]

  • 15. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
    Hoogervorst EL, Kalkers NF, van Winsen LML, Uitdehaag BM, Polman CH.
    Mult Scler; 2001 Oct 10; 7(5):335-9. PubMed ID: 11724450
    [Abstract] [Full Text] [Related]

  • 16. The reliability and validity of the Nottingham Extended Activities of Daily Living Scale in patients with multiple sclerosis.
    Nicholl CR, Lincoln NB, Playford ED.
    Mult Scler; 2002 Oct 10; 8(5):372-6. PubMed ID: 12356202
    [Abstract] [Full Text] [Related]

  • 17. A rapid screening tool for fatigue impact in multiple sclerosis.
    Kos D, Nagels G, D'Hooghe MB, Duportail M, Kerckhofs E.
    BMC Neurol; 2006 Aug 17; 6():27. PubMed ID: 16916440
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis.
    Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH.
    Mult Scler; 2006 Oct 17; 12(5):594-8. PubMed ID: 17086905
    [Abstract] [Full Text] [Related]

  • 19. How similar are commonly combined criteria for EDSS progression in multiple sclerosis?
    Kragt JJ, Nielsen IM, van der Linden FA, Uitdehaag BM, Polman CH.
    Mult Scler; 2006 Dec 17; 12(6):782-6. PubMed ID: 17263007
    [Abstract] [Full Text] [Related]

  • 20. The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis.
    van 't Hullenaar CAA, Coerver E, Kalkers NF, van Kempen Z, Koch M, Uitdehaag BMJ, Killestein J, Strijbis EMM.
    Mult Scler Relat Disord; 2021 Oct 17; 55():103165. PubMed ID: 34404022
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.